- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06018337
Исследование DB-1303 в сравнении с химиотерапией по выбору исследователя при метастатическом раке молочной железы
Фаза 3, рандомизированное, многоцентровое, открытое исследование DB-1303 в сравнении с химиотерапией по выбору исследователя у пациентов с низким уровнем рецептора эпидермального фактора роста 2 (HER2) и положительным по рецептору гормонов (HR+) метастатическим раком молочной железы, у которых заболевание прогрессировало. Эндокринная терапия (ЭТ) (DYNASTY-Breast02)
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry [IHC]2+/in situ hybridization [ISH]- and IHC 1+) population.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The study is a Phase III, Randomized, Multi-center, Open-label study in HER2-low, HR+ metastatic breast cancer subjects whose disease has progressed on at least 2 lines of prior ET or within 6 months of first line ET + Cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting. The primary purpose of the study is to determine the efficacy and safety of DB-1303/BNT323 compared with investigator's choice single agent chemotherapy in the target population. Approximately 532 subjects with HER2 IHC 2+/ISH- and IHC 1+ (HER2-low] expression will be randomized 1:1 across approximately 255 centers globally to receive either DB-1303 or investigator's choice single agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) until Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
Camperdown, New South Wales, Австралия, 2050
- Research Site 6108-0
-
Kingswood, New South Wales, Австралия, 2747
- Research Site 6116-0
-
Liverpool, New South Wales, Австралия, 2170
- Research Site 6109-0
-
Sydney, New South Wales, Австралия, 2109
- Research Site 6102-0
-
-
Queensland
-
Birtinya, Queensland, Австралия, 4575
- Research Site 6106-0
-
South Brisbane, Queensland, Австралия, 4101
- Research Site 6101-0
-
Southport, Queensland, Австралия, 4215
- Research Site 6107-0
-
Townsville, Queensland, Австралия, 4814
- Research Site 6104-0
-
-
South Australia
-
Adelaide, South Australia, Австралия, 2155
- Research Site 6110-0
-
-
Victoria
-
Bendigo, Victoria, Австралия, 3550
- Research Site 6103-0
-
St Albans, Victoria, Австралия, 3021
- Research Site 6105-0
-
Traralgon, Victoria, Австралия, 3844
- Research Site 6113-0
-
-
Western Australia
-
Perth, Western Australia, Австралия, 6009
- Research Site 6114-0
-
-
-
-
Buenos Aires
-
Bahía Blanca, Buenos Aires, Аргентина, B8001HXM
- Research Site 5411-0
-
CABA, Buenos Aires, Аргентина, C1015ABO
- Research Site 5414-0
-
La Plata, Buenos Aires, Аргентина, B1902CMJ
- Research Site 5405-0
-
Mar del Plata, Buenos Aires, Аргентина, 7600
- Research Site 5413-0
-
Quilmes, Buenos Aires, Аргентина, B1878GEG
- Research Site 5408-0
-
-
Ciudad Autonoma Buenos Aires
-
CABA, Ciudad Autonoma Buenos Aires, Аргентина, C1426ANZ
- Research Site 5403-0
-
Ciudad Autonoma Buenos Aires, Ciudad Autonoma Buenos Aires, Аргентина, 1431
- Research Site 5407-0
-
Ciudad Autonoma Buenos Aires, Ciudad Autonoma Buenos Aires, Аргентина, C1280AEB
- Research Site 5409-0
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Аргентина, X5008HHW
- Research Site 5412-0
-
-
Río Negro Province
-
Viedma, Río Negro Province, Аргентина, R8500ACE
- Research Site 5402-0
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, 2000
- Research Site 5401-0
-
Rosario, Santa Fe Province, Аргентина, S2000KZE
- Research Site 5406-0
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Аргентина, T4000AXL
- Research Site 5404-0
-
-
-
-
Brussels Capital
-
Brussels, Brussels Capital, Бельгия, 1200
- Research Site 3201-0
-
-
Gent
-
Ghent, Gent, Бельгия, 9000
- Research Site 3204-0
-
-
Jette
-
Jette, Jette, Бельгия, 1090
- Research Site 3205-0
-
-
Leuven
-
Leuven, Leuven, Бельгия, 3000
- Research Site 3203-0
-
-
Liege
-
Liège, Liege, Бельгия, 4000
- Research Site 3207-0
-
-
Roeselare
-
Roeselare, Roeselare, Бельгия, 8800
- Research Site 3202-0
-
-
-
-
-
Budapest, Венгрия, 1082
- Research Site 3603-0
-
Kecskemét, Венгрия, Kecskemet
- Research Site 3604-0
-
Salgótarján, Венгрия, 3100
- Research Site 3602-0
-
Tatabánya, Венгрия, 2800
- Research Site 3607-0
-
Zalaegerszeg, Венгрия, 8900
- Research Site 3605-0
-
-
Gyor
-
Győr, Gyor, Венгрия, 9024
- Research Site 3606-0
-
-
-
-
Bavaria
-
Erlangen, Bavaria, Германия, 91054
- Research Site 4907-0
-
-
Hesse
-
Wiesbaden, Hesse, Германия, 65199
- Research Site 4909-0
-
-
North Rhine-Westphalia
-
Bottrop, North Rhine-Westphalia, Германия, 46236
- Research Site 4904-0
-
Cologne, North Rhine-Westphalia, Германия, 50931
- Research Site 4902-0
-
Witten, North Rhine-Westphalia, Германия, 58452
- Research Site 4901-0
-
-
Saxony
-
Dresden, Saxony, Германия, 01307
- Research Site 4903-0
-
-
State of Berlin
-
Berlin, State of Berlin, Германия, 10967
- Research Site 4905-0
-
Berlin, State of Berlin, Германия, 13125
- Research Site 4906-0
-
-
-
-
-
Hong Kong, Гонконг, 00000
- Research Site 8504-0
-
Hong Kong, Гонконг, 0000
- Research Site 8501-0
-
Hong Kong, Гонконг, 0000
- Research Site 8503-0
-
-
Hong Kong
-
Hong Kong, Hong Kong, Гонконг
- Research Site 8502-0
-
Hong Kong, Hong Kong, Гонконг
- Research Site 8505-0
-
-
-
-
-
Ashdod, Израиль, 7747629
- Research Site 9710-0
-
Haifa, Израиль, 3109601
- Research Site 9706-0
-
Haifa, Израиль, 3436212
- Research Site 9708-0
-
Jerusalem, Израиль, 9103102
- Research Site 9702-0
-
Jerusalem, Израиль, 91120
- Research Site 9707-0
-
Kfar Saba, Израиль, 4428164
- Research Site 9703-0
-
Petah Tikva, Израиль, 4941492
- Research Site 9704-0
-
Ramat Gan, Израиль, 52621
- Research Site 9709-0
-
Rehovot, Израиль, 7610001
- Research Site 9705-0
-
Tel Aviv, Израиль, 64239
- Research Site 9701-0
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Испания, 08003
- Research Site 3410-0
-
Barcelona, Barcelona, Испания, 08023
- Research Site 3402-0
-
Barcelona, Barcelona, Испания, 08036
- Research Site 3404-0
-
Sant Cugat del Vallès, Barcelona, Испания, 08190
- Research Site 3403-0
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Испания, 15706
- Research Site 3409-0
-
-
Madrid
-
Madrid, Madrid, Испания, 28003
- Research Site 3416-0
-
Madrid, Madrid, Испания, 28040
- Research Site 3407-0
-
Madrid, Madrid, Испания, 28040
- Research Site 3414-0
-
Madrid, Madrid, Испания, 28050
- Research Site 3401-0
-
Majadahonda, Madrid, Испания, 28220
- Research Site 3406-0
-
Pozuelo de Alarcón, Madrid, Испания, 28223
- Research Site 3411-0
-
-
Malaga
-
Málaga, Malaga, Испания, 29016
- Research Site 3418-0
-
-
Málaga
-
Málaga, Málaga, Испания, 29010
- Research Site 3415-0
-
-
Navarre
-
Pamplona, Navarre, Испания, 31008
- Research Site 3405-0
-
-
Sevilla
-
Seville, Sevilla, Испания, 41009
- Research Site 3408-0
-
Seville, Sevilla, Испания, 41013
- Research Site 3413-0
-
Seville, Sevilla, Испания, 41013
- Research Site 3417-0
-
-
Valencia
-
Valencia, Valencia, Испания, 46010
- Research Site 3412-0
-
-
-
-
-
Naples, Италия, 80131
- Research Site 3909-0
-
-
Bergamo
-
Bergamo, Bergamo, Италия, 24125
- Research Site 3908-0
-
-
Brescia
-
Brescia, Brescia, Италия, 25124
- Research Site 3907-0
-
-
Catania
-
Catania, Catania, Италия, 95123
- Research Site 3901-0
-
-
Catanzaro
-
Catanzaro, Catanzaro, Италия, 88100
- Research Site 3903-0
-
-
Milano
-
Milan, Milano, Италия, 20132
- Research Site 3906-0
-
Milan, Milano, Италия, 20133
- Research Site 3911-0
-
Milan, Milano, Италия, 20141
- Research Site 3904-0
-
-
Pavia
-
Pavia, Pavia, Италия, 27100
- Research Site 3902-0
-
-
Verona
-
Verona, Verona, Италия, 37124
- Research Site 3905-0
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Канада, R3E 0V9
- Research Site 1007-0
-
-
Ontario
-
Brampton, Ontario, Канада, L6R 3J7
- Research Site 1003-0
-
Toronto, Ontario, Канада, M2K 1E1
- Research Site 1001-0
-
-
Quebec
-
Montreal, Quebec, Канада, H3T 1E2
- Research Site 1004-0
-
Montreal, Quebec, Канада, H3T 1M5
- Research Site 1005-0
-
Montreal, Quebec, Канада, H4A 3J1
- Research Site 1006-0
-
Sherbrooke, Quebec, Канада, J1H5N4
- Research Site 1002-0
-
-
-
-
Anhui
-
Bengbu, Anhui, Китай, 233004
- Research Site 8639-0
-
Hefei, Anhui, Китай, 230088
- Research Site 8640-0
-
Hefei, Anhui, Китай, 230601
- Research Site 8614-0
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100021
- Research Site 8601-0
-
Beijing, Beijing Municipality, Китай, 100071
- Research Site 8625-0
-
Beijing, Beijing Municipality, Китай, 100142
- Research Site 8653-0
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Китай, 400030
- Research Site 8627-0
-
-
Fujian
-
Fuzhou, Fujian, Китай, 350015
- Research Site 8651-0
-
Xiamen, Fujian, Китай, 361003
- Research Site 8638-0
-
-
Gansu
-
Lanzhou, Gansu, Китай, 730000
- Research Site 8630-0
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510000
- Research Site 8604-0
-
Guangzhou, Guangdong, Китай, 510060
- Research Site 8628-0
-
Huizhou, Guangdong, Китай, 516003
- Research Site 8621-0
-
Zhuhai, Guangdong, Китай, 519000
- Research Site 8622-0
-
-
Guangxi
-
Nanning, Guangxi, Китай, 530021
- Research Site 8615-0
-
-
Hebei
-
Baoding, Hebei, Китай, 071030
- Research Site 8629-0
-
Shijiazhuang, Hebei, Китай, 50011
- Research Site 8645-0
-
-
Heilongjiang
-
Harbin, Heilongjiang, Китай, 150081
- Research Site 8619-0
-
-
Henan
-
Anyang, Henan, Китай, 455000
- Research Site 8649-0
-
Luoyang, Henan, Китай, 471003
- Research Site 8609-0
-
Weihui, Henan, Китай, 453100
- Research Site 8648-0
-
Zhengzhou, Henan, Китай, 450000
- Research Site 8605-0
-
Zhengzhou, Henan, Китай, 450003
- Research Site 8623-0
-
-
Hubei
-
Wuhan, Hubei, Китай, 430022
- Research Site 8637-0
-
Wuhan, Hubei, Китай, 430079
- Research Site 8608-0
-
Xiangyang, Hubei, Китай, 430079
- Research Site 8633-0
-
-
Hunan
-
Changsha, Hunan, Китай, 410005
- Research Site 8635-0
-
Yongzhou, Hunan, Китай, 425000
- Research Site 8654-0
-
-
Jiangsu
-
Huai'an, Jiangsu, Китай, 223300
- Research Site 8646-0
-
Nanjing, Jiangsu, Китай, 210029
- Research Site 8607-0
-
Xuzhou, Jiangsu, Китай, 221009
- Research Site 8624-0
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 330009
- Research Site 8631-0
-
-
Jilin
-
Changchun, Jilin, Китай, 130000
- Research Site 8612-0
-
Changchun, Jilin, Китай, 130021
- Research Site 8618-0
-
Changchun, Jilin, Китай, 130041
- Research Site 8644-0
-
-
Liaoning
-
Dalian, Liaoning, Китай, 116027
- Research Site 8636-0
-
Shenyang, Liaoning, Китай, 110001
- Research Site 8643-0
-
Shenyang, Liaoning, Китай, 110042
- Research Site 8642-0
-
-
Shandong
-
Jinan, Shandong, Китай, 250117
- Research Site 8634-0
-
Jining, Shandong, Китай, 272029
- Research Site 8613-0
-
Linyi, Shandong, Китай, 276000
- Research Site 8610-0
-
Weihai, Shandong, Китай, 264200
- Research Site 8650-0
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200025
- Research Site 8603-0
-
Shanghai, Shanghai Municipality, Китай, 200032
- Research Site 8602-0
-
-
Shanxi
-
Xi’an, Shanxi, Китай, 710061
- Research Site 8611-0
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610041
- Research Site 8606-0
-
Neijiang, Sichuan, Китай, 641000
- Research Site 8626-0
-
Zigong, Sichuan, Китай, 643000
- Research Site 8647-0
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Китай, 300453
- Research Site 8617-0
-
-
Xinjiang
-
Ürümqi, Xinjiang, Китай, 830000
- Research Site 8616-0
-
-
Yunnan
-
Kunming, Yunnan, Китай, 650118
- Research Site 8632-0
-
-
Zhejiang
-
Hangzhou, Zhejiang, Китай, 310000
- Research Site 8652-0
-
Hangzhou, Zhejiang, Китай, 310016
- Research Site 8620-0
-
Hangzhou, Zhejiang, Китай, 310022
- Research Site 8641-0
-
-
-
-
-
Krakow, Польша, 31-501
- Research Site 4804-0
-
Poznan, Польша, 61-866
- Research Site 4801-0
-
Warsaw, Польша, 04-141
- Research Site 4805-0
-
Wroclaw, Польша, 53-673
- Research Site 4809-0
-
-
Rzeszów
-
Rzeszów, Rzeszów, Польша, 35-021
- Research Site 4802-0
-
-
Torun
-
Torun, Torun, Польша, 87-100
- Research Site 4807-0
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Польша, 90-302
- Research Site 4803-0
-
-
-
-
Cornwall
-
Truro, Cornwall, Соединенное Королевство, TR1 3LJ
- Research Site 4404-0
-
-
Greater London
-
London, Greater London, Соединенное Королевство, EC1A 7BE
- Research Site 4408-0
-
London, Greater London, Соединенное Королевство, NW1 2PG
- Research Site 4411-0
-
London, Greater London, Соединенное Королевство, SE1 9RT
- Research Site 4406-0
-
London, Greater London, Соединенное Королевство, SW36JJ
- Research Site 4416-0
-
London, Greater London, Соединенное Королевство, W1G 6AD
- Research Site 4409-0
-
Southampton, Greater London, Соединенное Королевство, NW1 2PG
- Research Site 4413-0
-
-
Greater Manchester
-
Manchester, Greater Manchester, Соединенное Королевство, M20 4BX
- Research Site 4402-0
-
-
Kent
-
Maidstone, Kent, Соединенное Королевство, ME16 9QQ
- Research Site 4415-0
-
-
Middlesex
-
Middlesex, Middlesex, Соединенное Королевство, HA6 2RN
- Research Site 4403-0
-
-
Nottingham
-
Nottingham, Nottingham, Соединенное Королевство, NG5 1PB
- Research Site 4401-0
-
-
Somerset
-
Bath, Somerset, Соединенное Королевство, BA1 3NG
- Research Site 4414-0
-
-
South Glamorgan
-
Cardiff, South Glamorgan, Соединенное Королевство, CF14 2TL
- Research Site 4410-0
-
-
Strathclyde
-
Glasgow, Strathclyde, Соединенное Королевство, G12 0YN
- Research Site 4405-0
-
-
West Yorkshire
-
Leeds, West Yorkshire, Соединенное Королевство, LS9 7TF
- Research Site 4407-0
-
-
-
-
Arizona
-
Tucson, Arizona, Соединенные Штаты, 85704
- Research Site 1141-0
-
-
California
-
Fullerton, California, Соединенные Штаты, 92835
- Research Site 1114-0
-
Los Angeles, California, Соединенные Штаты, 90095
- Research Site 1107-0
-
Orange, California, Соединенные Штаты, 92868-3201
- Research Site 1118-0
-
Sacramento, California, Соединенные Штаты, 95814
- Research Site 1143-0
-
Santa Barbara, California, Соединенные Штаты, 93105
- Research Site 1132-0
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Research Site 1137-0
-
Lone Tree, Colorado, Соединенные Штаты, 80124
- Research Site 1129-0
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32256
- Research Site 1154-0
-
Miami, Florida, Соединенные Штаты, 33136
- Research Site 1145-0
-
Orange City, Florida, Соединенные Штаты, 32763
- Research Site 1150-0
-
Palm Bay, Florida, Соединенные Штаты, 32909
- Research Site 1125-0
-
-
Georgia
-
Athens, Georgia, Соединенные Штаты, 30607
- Research Site 1155-0
-
Savannah, Georgia, Соединенные Штаты, 31405
- Research Site 1110-0
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Research Site 1147-0
-
Chicago Ridge, Illinois, Соединенные Штаты, 60415
- Research Site 1124-0
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46804
- Research Site 1152-0
-
-
Kansas
-
Merriam, Kansas, Соединенные Штаты, 66204
- Research Site 1106-0
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40202
- Research Site 1104-0
-
-
Maryland
-
Silver Spring, Maryland, Соединенные Штаты, 20904
- Research Site 1122-0
-
-
Missouri
-
Kansas City, Missouri, Соединенные Штаты, 64111
- Research Site 1109-0
-
-
New Jersey
-
Camden, New Jersey, Соединенные Штаты, 08103
- Research Site 1158-0
-
Florham Park, New Jersey, Соединенные Штаты, 07932
- Research Site 1111-0
-
-
New Mexico
-
Sante Fe, New Mexico, Соединенные Штаты, 87505
- Research Site 1157-0
-
-
New York
-
Staten Island, New York, Соединенные Штаты, 10314
- Research Site 1148-0
-
Westbury, New York, Соединенные Штаты, 11590
- Research Site 1105-0
-
-
North Carolina
-
Chapel Hil, North Carolina, Соединенные Штаты, 27599
- Research Site 1144-0
-
-
Ohio
-
Akron, Ohio, Соединенные Штаты, 44305
- Research Site 1138-0
-
Cincinnati, Ohio, Соединенные Штаты, 45220
- Research Site 1160-0
-
-
Oregon
-
Eugene, Oregon, Соединенные Штаты, 97401-8122
- Research Site 1133-0
-
Tigard, Oregon, Соединенные Штаты, 97223
- Research Site 1126-0
-
-
Pennsylvania
-
Broomall, Pennsylvania, Соединенные Штаты, 19008
- Research Site 1134-0
-
Horsham, Pennsylvania, Соединенные Штаты, 19044
- Research Site 1123-0
-
-
Tennessee
-
Knoxville, Tennessee, Соединенные Штаты, 37909
- Research Site 1149-0
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Research Site 1102-0
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Research Site 1159-0
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75246
- Research Site 1101-0
-
Denison, Texas, Соединенные Штаты, 75020
- Research Site 1116-0
-
Houston, Texas, Соединенные Штаты, 77030
- Research Site 1115-0
-
San Antonio, Texas, Соединенные Штаты, 78240
- Research Site 1117-0
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84124
- Research Site 1130-0
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Research Site 1108-0
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Research Site 1131-0
-
Roanake, Virginia, Соединенные Штаты, 24014
- Research Site 1127-0
-
-
-
-
-
Adana, Турция (Туркие), 01230
- Research Site 9001-0
-
Ankara, Турция (Туркие), 06010
- Research Site 9002-0
-
Ankara, Турция (Туркие), 06100
- Research Site 9006-0
-
Ankara, Турция (Туркие), 06105
- Research Site 9003-0
-
Ankara, Турция (Туркие), 06800
- Research Site 9004-0
-
Diyarbakır, Турция (Туркие), 21280
- Research Site 9009-0
-
Istanbul, Турция (Туркие), 34147
- Research Site 9008-0
-
Istanbul, Турция (Туркие), 34890
- Research Site 9012-0
-
Izmir, Турция (Туркие), 35575
- Research Site 9010-0
-
Mersin, Турция (Туркие), 33240
- Research Site 9011-0
-
Samsun, Турция (Туркие), 55139
- Research Site 9007-0
-
-
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Франция, 13915
- Research Site 3311-0
-
-
Charente Maritime
-
La Rochelle, Charente Maritime, Франция, 17019
- Research Site 3303-0
-
-
Doubs
-
Besançon, Doubs, Франция, 25000
- Research Site 3312-0
-
-
Gard
-
Nîmes, Gard, Франция, 30029
- Research Site 3308-0
-
-
Gironde
-
Bordeaux, Gironde, Франция, 33077
- Research Site 3314-0
-
-
Haute Garonne
-
Toulouse, Haute Garonne, Франция, 31059
- Research Site 3305-0
-
-
Haute Vienne
-
Limoges, Haute Vienne, Франция, 87000
- Research Site 3309-0
-
-
Herault
-
Montpellier, Herault, Франция, 34070
- Research Site 3304-0
-
-
Loire Atlantique
-
Saint-Herblain, Loire Atlantique, Франция, 44800
- Research Site 3310-0
-
-
Maine et Loire
-
Angers, Maine et Loire, Франция, 49055
- Research Site 3301-0
-
-
Nord
-
Lille, Nord, Франция, 59020
- Research Site 3315-0
-
-
Paris
-
Paris, Paris, Франция, 75010
- Research Site 3316-0
-
-
Pyrenees Atlantiques
-
Bayonne, Pyrenees Atlantiques, Франция, 64109
- Research Site 3306-0
-
-
Rhone
-
Pierre-Bénite, Rhone, Франция, 69495
- Research Site 3318-0
-
-
Seine Maritime
-
Rouen, Seine Maritime, Франция, 76038
- Research Site 3313-0
-
-
Vaculuse
-
Avignon, Vaculuse, Франция, 84918
- Research Site 3307-0
-
-
Val de Marne
-
Créteil, Val de Marne, Франция, 94010
- Research Site 3302-0
-
-
-
-
-
Cheonan, Южная Корея, 31151
- Research Site 8212-0
-
Seoul, Южная Корея, 03080
- Research Site 8207-0
-
Seoul, Южная Корея, 06273
- Research Site 8213-0
-
Ulsan, Южная Корея, 44033
- Research Site 8214-0
-
-
Busan
-
Busan, Busan, Южная Корея, 49201
- Research Site 8208-0
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Южная Корея, 26426
- Research Site 8211-0
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Южная Корея, KS009
- Research Site 8204-0
-
Seoul, Gyeonggi-do, Южная Корея, 2841
- Research Site 8201-0
-
Suwon, Gyeonggi-do, Южная Корея, 16499
- Research Site 8202-0
-
-
Incheon
-
Incheon, Incheon, Южная Корея, 21565
- Research Site 8209-0
-
-
Seoul
-
Seoul, Seoul, Южная Корея, 3722
- Research Site 8206-0
-
Seoul, Seoul, Южная Корея, 5505
- Research Site 8210-0
-
Seoul, Seoul, Южная Корея, 6591
- Research Site 8203-0
-
Seoul, Seoul, Южная Корея, 8308
- Research Site 8205-0
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
1. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).
2. Pathologically documented breast cancer that:
- Is advanced or metastatic
- Has HER2-low expression (IHC 1+ or IHC 2+/ISH-) as determined by the central laboratory result.
- Was never previously reported as HER2-positive (IHC 3+ or ISH+) as per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
- Is documented as HR+ (either estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR ≥1%]) per ASCO/CAP guidelines (Allison et al 2020).
3. Must have an adequate tumor tissue sample available for assessment of HER2 by central laboratory, in formalin fixation and paraffin embedding (FFPE) blocks based on a mandatory FFPE tumor sample preferably obtained at the time of metastatic disease or later;
4. Eastern Cooperative Oncology Group performance status of 0 or 1.
5. Must have had either:
- Disease progression on endocrine therapy + CDK4/6 inhibitor within 6 months of starting first line treatment for metastatic disease and considered appropriate for chemotherapy as the next treatment by the investigator, OR
- Disease progression on at least 2 previous lines of ET with or without a targeted therapy (such as CDK4/6, mammalian target of rapamycin [mTOR] or phosphoinositide 3-kinase [PI3-K] inhibitors) administered for the treatment of metastatic disease.
6. No prior chemotherapy for advanced or metastatic breast cancer. Subjects who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to diagnosis of advanced or metastatic disease) of >12 months.
7. Life expectancy ≥12 weeks at screening.
8. Subjects must have at least one measurable lesion as defined per RECIST v1.1 (For bone only disease, subjects with lytic or mixed lytic bone lesions that can be measured by CT or MRI are eligible; subjects with sclerotic/osteoblastic bone lesions are not eligible).
9. Has LVEF ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before randomization.
10. Adequate organ and bone marrow function within 14 days before randomization.
11. Has adequate treatment washout period before randomization.
12. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of study treatment.
Women of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.
13. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 7 months after the last dose of study treatment. Not all methods of contraception are highly effective. Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject for the duration of the study treatment and the drug washout period (7 months). Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female subjects must not donate ova, or retrieve for their own use, from the time of screening and throughout the study treatment period, and for at least 7 months after the last dose of study treatment. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to randomization in this study.
14. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening and throughout the duration of the study treatment and the washout period (4 months after the last dose of DB-1303, 6 months after the last dose of paclitaxel or nab-paclitaxel, and 3 months after the last dose of capecitabine). Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject for the duration of the study treatment and the drug washout period. Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception. It is strongly recommended for the female partners of a male subject also use at least one highly effective method of contraception throughout this period. In addition, male subjects should refrain from fathering a child or donating sperm throughout the duration of the study and the washout period (4 months after the last dose of DB-1303, 6 months after the last dose of paclitaxel or nab paclitaxel, and 3 months after the last dose of capecitabine). Preservation of sperm should be considered prior to randomization in this study.
15. Must be able and willing to comply with the protocol requirements and must sign and date the informed consent form prior to any screening evaluations.
Exclusion Criteria:
- Ineligible for all options in the investigator's choice chemotherapy arm.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events or compromise the ability of the subject to give written informed consent.
- Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring repeated drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the randomization.
- Uncontrolled or significant cardiovascular disease
- Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis which needs glucocorticoids and antibiotics) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
- Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline or Grade ≤ 2 anemia.
- Previous treatment with anti-HER2 therapy.
- Prior treatment with antibody-drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor.
- Prior randomization or treatment in a previous DB-1303/BNT323 study regardless of treatment assignment.
- Has substance abuse or any other medical conditions such as psychological conditions, that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
- Individuals who are dependent on the Sponsor, clinical site, or Investigator (e.g., is an employee of the Sponsor or the clinical trial site, a dependent of the Investigator, or any site staff member otherwise supervised by the Investigator).
- Individuals who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities, in accordance with local regulations.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: DB-1303/BNT323
Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W |
IV |
|
Активный компаратор: investigator's choice single agent chemotherapy
Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel:80 mg/m2, IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. |
Oral IV IV |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival (PFS) in the HR+, HER2-low population
Временное ограничение: Up to approximately 51 months
|
PFS by BICR according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall survival (OS) in the HR+, HER2-low population
Временное ограничение: Up to approximately 51 months
|
OS in the HR+, HER2-low population |
Up to approximately 51 months
|
|
Objective response rate (ORR) in the HR+, HER2-low population
Временное ограничение: Up to approximately 51 months
|
ORR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
|
PFS by Investigator assessment
Временное ограничение: Up to approximately 51 months
|
PFS by Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
|
Duration of response (DoR) in the HR+, HER2-low population
Временное ограничение: Up to approximately 51 months
|
DoR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
|
Treatment-emergent adverse events (TEAEs)
Временное ограничение: from the time of the subject signing the informed consent form (ICF) until the follow-up period is completed (35 days after the last dose of study treatment
|
TEAEs per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
from the time of the subject signing the informed consent form (ICF) until the follow-up period is completed (35 days after the last dose of study treatment
|
|
Serious adverse events (SAEs)
Временное ограничение: from the time of the subject signing the ICF until the follow-up period is completed (35 days after the last dose of study treatment
|
SAEs per NCI CTCAE v5.0 |
from the time of the subject signing the ICF until the follow-up period is completed (35 days after the last dose of study treatment
|
|
Patient reported outcomes (PROs): European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30
Временное ограничение: Up to approximately 51 months
|
Change from baseline in the functioning/symptom/global quality of life (QoL) subscales of EORTC QLQ-C30. Scale scores range from 0-100. For functioning and global QoL scales, higher scores indicate better functioning or global health status. For symptom scales, higher scores indicate greater symptom burden. |
Up to approximately 51 months
|
|
Patient reported outcomes (PROs): EORTC QLQ-BR45
Временное ограничение: Up to approximately 51 months
|
Change from baseline in the functioning/symptom subscales of EORTC QLQ-BR45. Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
Up to approximately 51 months
|
|
Patient reported outcomes (PROs): European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)
Временное ограничение: Up to approximately 51 months
|
Change from baseline in EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. VAS score range from 0-100, higher scores indicate better health status. |
Up to approximately 51 months
|
|
European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)
Временное ограничение: Up to approximately 51 months
|
EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. The change from baseline value will be reported. |
Up to approximately 51 months
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Joyce O'Shaughnessy, PHD, Texas Oncology - Baylor Charles A. Sammons Cancer center
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Кожные заболевания
- Заболевания груди
- Заболевания кожи и соединительной ткани
- Новообразования молочной железы
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Нуклеиновые кислоты, нуклеотиды и нуклеозиды
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Таксииды
- Циклодеканы
- Diterpenes
- Дезоксицитидин
- Цитидин
- Пиримидиновые нуклеозиды
- Пиримидины
- Нуклеозиды
- Урацил
- Пиримидиноны
- Дезоксирибонуклеозиды
- Флуорурацил
- Капецитабин
- Паклитаксел
- 130-нм-паклитаксел
Другие идентификационные номера исследования
- DB-1303-O-3002
- CTR20233708 (Другой идентификатор: CENTER FOR DRUG EVALUATION, NMPA)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .